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SUMMARY
Information on the incidence of Chlamydia trachomatis (CT) is essential for models of the
effectiveness and cost-effectiveness of screening programmes. We developed two independent
estimates of CT incidence in women in England: one based on an incidence study, with estimates
‘recalibrated’ to the general population using data on setting-speciﬁc relative risks, and allowing
for clearance and re-infection during follow-up; the second based on UK prevalence data, and
information on the duration of CT infection. The consistency of independent sources of data on
incidence, prevalence and duration, validates estimates of these parameters. Pooled estimates of
the annual incidence rate in women aged 16–24 and 16–44 years for 2001–2005 using all these
data were 0·05 [95% credible interval (CrI) 0·035–0·071] and 0·021 (95% CrI 0·015–0·028),
respectively. Although, the estimates apply to England, similar methods could be used in other
countries. The methods could be extended to dynamic models to synthesize, and assess the
consistency of data on contact and transmission rates.
Key words: Bayesian analysis, Chlamydia, evidence synthesis, incidence, multi-parameter evidence
synthesis.
INTRODUCTION
About 110000 cases of Chlamydia trachomatis (CT)
were diagnosed in women in England in 2009 [1].
However, CT infection is often asymptomatic and
undiagnosed, which is one of the key motivating fac-
tors for screening. Dynamic models of disease trans-
mission are commonly used to assess the potential
impact of screening and its cost-effectiveness [2–4],
and these models need to be consistent with observed
information on the age-speciﬁc incidence of infection.
One study that provides estimates of CT incidence
in England has been published [5]. Women aged
16–24 years were screened for Chlamydia in General
Practitioner (GP), Family Planning (FP), and Sex-
ually Transmitted Disease clinic (STD) settings in
two areas in England, and were followed prospectively
at 6-month intervals for 6–18 months to assess CT
infection and re-infection. However, this study is
restricted to clinic patients and it does not address
incidence in the English general population. In
addition, due to the interval-censored observations
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in the study, it is possible for women to have both
acquired and cleared the infection during the periods
between observations, leading to under-estimation of
incidence. This was not accounted for in the original
paper [5].
This paper sets out to produce a set of age-group-
speciﬁc estimates of CT incidence in the general popu-
lation of women in England based on all available
evidence. There are several novel aspects in our
approach. First, we re-analysed the data from the
LaMontagne et al. [5] incidence study accounting for
CT clearance, informing clearance rate from a recent
synthesis of the duration of asymptomatic infection.
Second, we use information on setting-speciﬁc pre-
valence [6] of CT in the UK, which included estimates
in the general population as well as in GP, FP, and
STD settings, to ‘recalibrate’ the estimated incidence
rates from LaMontagne to the general population set-
ting. Third, we exploit the well known epidemiological
relationship: prevalence= incidence×duration to gen-
erate an independent set of incidence estimates based
on prevalence and duration data. This provides a
degree of independent validation for the estimates
obtained directly from the incidence study. Finally,
we produce a coherent set of estimates of age-speciﬁc
incidence and prevalence, and duration in women
in the general population that both, conform to the
appropriate epidemiological relationships, and are
based on all the available data. This is an application
of multi-parameter evidence synthesis [7, 8] to
Chlamydia epidemiology.
METHODS
Multi-parameter evidence synthesis
Multi-parameter evidence synthesis (MPES) is a
method for estimating models by statistically combin-
ing all the available information on model parameters
and functions of parameters [7, 8]. The uncertainty in
the data inputs is taken into account and propagated
through the model. In MPES parameters are deﬁned
as basic or functional. The model is fully speciﬁed
by the basic parameters [9]. All functional parameters
can be written as functions of these basic parameters.
They are important either because some data informs
a functional parameter, or because the distribution
and summary statistics for the functional parameter
are of interest.
Data are available on incidence, prevalence, and
duration, and also on risk factors. Because there is
information on more functions of parameters than
there are parameters, it is possible to assess the con-
sistency of the evidence. A schematic directed acyclic
graph (DAG) (Fig. 1) shows the relationships between
the sources of data and the model parameters, and
spells out their mathematical form. The data sources
are shown in clear rectangles, and informative priors
in light grey rectangles. Basic parameters are shown
in shaded ellipses, and functional parameters in clear
ellipses. All basic parameters that do not have an
arrow pointing to them from an informative prior
have uninformative priors which are not shown on
the diagram. We estimated the models using the
Bayesian Markov Chain Monte Carlo (MCMC)
package WinBUGS [10]. With WinBUGS software
the user needs to specify the prior distributions on
the basic parameters, to specify the likelihood for
each of the data observations, and specify the math-
ematical relations, as shown in the ﬁgure, that link
them. Full details of the statistical model are given
in Appendix 1.
Models and data sources
An attempt was made to identify data sources on inci-
dence and prevalence of CT in the UK. A formal sys-
tematic review was not conducted, but papers were
identiﬁed from recent reviews and synthesis exercises.
Only one published report on incidence was identiﬁed
[5], and a recent synthesis of UK CT prevalence data
was also used [6]. Information on CT duration was
based on a recent synthesis [11] described below.
The information in Tables 1–4 represents all the infor-
mation incorporated in the synthesis. Below we set out
the assumptions that were made about the processes
that generated the data, and the main features of the
synthesis model. We begin by discussing the duration
of CT infection which is required for all subsequent
analyses.
Duration of CT infection
The mean duration of infection, Δ, can be expressed
as a weighted average of the length of asymptomatic
(untreated) infection ΔA and symptomatic (treated)
infection ΔS,
Δ = Δφ+ ΔA.(1− φ), (1)
with φ being the proportion of incident infections in
which symptoms develop. In the Discussion section
we show that results would have been similar
if we considered durations of treated and untreated
infections instead.
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For the duration of asymptomatic CT infections,
ΔA, we use an estimate of 1·36 (95% CrI 1·11–1·62)
years, based on a previous evidence synthesis of
studies on CT duration in asymptomatic women
[11]. This was a synthesis of nine studies identiﬁed
from recent reviews [12–14], four that recruited
asymptomatic infected women in STD clinic settings,
and ﬁve studies based on population screening. Evi-
dence was presented that these approximately rep-
resented incident and prevalent infections, respect-
ively. The authors ﬁtted mixtures of exponential mod-
els to these data. The estimates used here (Table 1)
were based on a model that assumed CT infections
clear at a constant rate.
Studies of CT duration have the inherent limitation
that patients may clear infection and be re-infected
during the follow-up period. For this reason we con-
sider same-partner re-infections, which microbiological
evidence suggest comprise the great majority of re-
infections [15], to be part of a continuous episode.
Proportions infected, re-infected by
age and setting (LaMontagne [5])
Setting-specific prevalence
ratios (Adams [6])
Infection/Re-infection weights
(LaMontagne [5])
Age-specific population
prevalence (Adams [6])
Infection ratesa,s
λa,s,1 = ρ sγ aλ1,1,1 
Re-infection ratesa,s
Force of infection, population
Proportion symptomatic
(Geisler [16])Clearance rate, A
λ A = 1/
 
∆A 
Clearance rate, S
λS = 1/
 
∆S Informative prior
Duration symptomatic, ∆S
Duration asymptomatic, ∆A
Duration
synthesis,
Price [11])
Average duration
∆  = ∆S.ϕ +∆A.(1–ϕ)
Proportions infected at time t, LaMontagne study
Average popn. incidence
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λs + λa,s,i.e λ
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Fig. 1. Directed acyclic graph (DAG) of the evidence network. The data sources are shown in clear rectangles, and
informative priors in light grey rectangles. Basic parameters are shown in shaded ellipses, and functional parameters in
clear ellipses. The arrows show the direction of ﬂow. Light arrows point to data, heavy arrows indicate functional
relationships between parameters, which are set out as equations. Data may be available to provide evidence on either
basic or functional parameters. All basic parameters that do not have an arrow pointing to them from an informative
prior have uninformative priors which are not shown on the diagram. The ‘basic’ parameters are: λ1,1,1 the infection rate
in age group 1, setting 1; γa the hazard ratio for infection in age group a relative to group 1 (age 16–17 years); ρs the
hazard ratio for infection in setting s relative to setting 1 (GP setting); ηs the setting-speciﬁc reinfection:infection rate ratio;
pa,GP the proportion of patients at recruitment in the GP attenders in age group a in the LaMontagne study that were in
the re-infection group reweighted to account for differential recruitment; ΔA and ΔS, the durations of asymptomatic and
symptomatic infection; φ the proportion of incident infections in which symptoms develop. Functional parameters are:
λA, λS clearance rates of asymptomatic and symptomatic infection; λa,s,i incidence in age a, setting s, for infections (i=1)
and re-infections (i=2); κ (t)a,s,i proportion infected in that group after t years (for the LaMontagne study t=0·5);
λ˜FOIa,pop the force of infection and λ˜
INC
a,pop the incidence rate in the general population; Δ the average duration of infection.
πa,pop, the general population prevalence at age a is either a basic or functional parameter depending on whether separate
incidence estimates (methods A and B are performed in parallel) or the full synthesis model is being used. The black bar
indicates where the network can be cut to obtain separate estimates of incidence. (Further explanation is given in the text
and the statistical Appendix).
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The proportion of CT infections, φ, in which symp-
toms develop can be estimated from studies where
asymptomatic women within a few days of exposure
are followed without treatment to determine if symp-
toms develop, and we have interpreted studies of
asymptomatic women attending for STD testing as
studies of this type. This interpretation is supported
by the synthesis of studies on CT duration described
above [11]. We identiﬁed only one such study report-
ing the proportion of incident CT in which symptoms
develop [11]. This found that 26 out of a total of 115
women developed symptoms, estimating φ at 23%
(95% CI 16–31) [16].
Duration of symptomatic infection, ΔS, is deﬁned as
the time between the point at which the patient
becomes infected, and the point at which the infection
is diagnosed, or the patient is empirically treated and
the infection is cleared. This could be derived from
information on the incubation period of CT and
studies of time taken to seek healthcare in women
subsequently diagnosed with CT. A recent literature
search [12] found no data on incubation period, and
although there were studies of time to seek healthcare
in women with genital symptoms, speciﬁc information
on those diagnosed with CT was not found. We have
placed an informative prior on the time from infection
to diagnosis assuming it is uniformly distributed
between 4 and 8 weeks, and that once diagnosed a
woman would not participate in a prevalence survey.
We assess sensitivity to this by ﬁtting a model where
the duration of symptomatic infection varies uniformly
from 3 to 12 weeks.
Table 1. Data on duration (years) of Chlamydia trachomatis infection
Parameter Mean (95% CrI) Source
Duration of asymptomatic infection 1·36 (1·11–1·62) Price et al. [11]
Duration of symptomatic infection 0·115 (0·079–0·151) See text
Duration of symptomatic infection (sensitivity analysis) 0·144 (0·062–0·227) See text
Proportion of incident infections in which symptoms develop 0·231 (0·159–0·311) Geisler et al. [16]
CrI, Credible interval.
Table 2. Data derived from tables 2 and 4 from
LaMontagne et al. [5] on infection and re-infection
rates per 100 women years: numerators r and
denominators n
Setting Age (yr)
Infection Re-infection
r Rate n* r Rate n*
GP
16–17 4 11·2 73 5 86·2 14
18–20 3 3·1 195 7 22·8 65
21–24 4 4·3 188 10 26·9 79
FP
16–17 9 9·5 194 13 29·4 95
18–20 5 3·7 273 12 19·9 127
21–24 7 7·1 201 5 16·6 63
STD
16–17 5 10·1 102 6 32·3 40
18–20 16 14·1 235 15 22·8 139
21–24 9 7·5 245 5 12·8 81
GP, General practitioner; FP, family planning; STD,
sexually transmitted disease clinic.
* n is estimated as the total number of 6-month follow-up
periods (events were assumed to happen halfway between ob-
servations when the rates were estimated in LaMontagne).
This has been calculated from the reported rates and num-
bers of events.
Table 3. Estimated prevalence of Chlamydia
trachomatis in females in the general population
reported in table 4 in Adams et al. [6]
Age (yr) Prevalence (95% CI)
18–19 0·048 (0·032–0·076)
20–24 0·032 (0·021–0·049)
25–29 0·015 (0·010–0·025)
30–44 0·008 (0·005–0·013)
CI, Conﬁdence interval.
Table 4. Reported adjusted odds ratios for the effect of
setting on Chlamydia prevalence in females in the UK,
from table 3 in Adams et al. [6]
Setting OR (95% CI)
General population vs. GP 0·6 (0·37–0·95)
FP vs. GP 1·27 (1·00–1·62)
STD vs. GP 2·39 (0·72–3·33)
OR, Odds ratio; CI, conﬁdence interval; GP, general prac-
titioner; FP, family planning; STD, sexually transmitted dis-
ease clinic.
Incidence of Chlamydia in England 565
CT incidence data
The only study of CT incidence in England is
LaMontagne et al. [5]. Women aged 16–24 years
were screened for Chlamydia in GP, FP, and STD
settings in two areas in England in 2003–2004, and
were followed prospectively at 6-month intervals for
6–18 months to assess CT infection and re-infection.
A ligase chain reaction (LCR) test was used, for
which we assumed 100% sensitivity and speciﬁcity.
Women found positive were treated. Table 2 gives
the proportions of 6-month-long observations in
which CT-negative women were CT positive on
follow-up. These are divided into ‘infections’ and
‘re-infections’: the latter being infections observed in
women who were CT positive on recruitment or
were infected during the follow-up period. The data
are reported for age groups (a=1, 16–17 years; a=2,
18–20 years; a=3, 21–24 years).
Regression model to estimate infection and re-infection
rates by age and setting
We model the infection rates as a function of a base-
line infection rate λ1,1,1 multiplied by the between
setting hazard ratios ρs and the between age-group
hazard ratios γa. The age- and setting-speciﬁc
re-infection rates λa,s,2 equal the respective infection
rate multiplied by a setting-speciﬁc re-infection hazard
ratio ηs [equation (2)]. Other regression models are
considered in Appendix 2:
λa,s,1 = γa ρsλ111 and λa,s,2 = ηs λa,s,1, (2)
The infection rates λa,s,1 in equation (2) are
informed by the data in Table 2, which shows the
number of initially uninfected women in each age
and setting who were found to be infected after
a 6-month follow-up period. However the mathemat-
ical relationship between the infection rates in
each group and the proportions infected κ (t)a,s,i at
the end of a period of time length t is complex.
The formula shown in Figure 1 allows for the fact
that in the LaMontagne data it is possible for a
woman to clear infection spontaneously or through
treatment, and then re-acquire infection within
the 6-month follow-up. It is necessary therefore to
take account of the clearance rates of symptomatic
and asymptomatic infection, and the proportion of
incident infections that become symptomatic (see
Appendix 1).
Estimation of force of infection (FOI)
The infection and re-infection rates can be used to esti-
mate the mean FOI, λ˜FOIa,s , in the CT-negative women
in each setting and age group using equation (3):
λ˜FOIa,s = (1− pa,s).λa,s,1 + pa,s.λa,s,2, (3)
where the weights pa,s are given by the prevalence
of CT in each setting observed in the LaMontagne
study (Appendix 1). However, as the LaMontagne
study only samples from GP, STD, and FP settings it
is necessary to turn to a third source of evidence, CT
prevalence, to map these estimates of FOI to estimates
for the general population.
CT prevalence
CT prevalence varies by age and setting. Table 3 shows
estimates of CT prevalence by age in the general popu-
lation from a logistic regression of UK prevalence
studies [6] identiﬁed by a systematic review in 2004.
These data inform the absolute prevalence in 18- to
19-year-olds, π1,pop (the youngest age group in the
study), and the relative risk RRa of infection in the
generic age group a relative to age 18–19 years so that:
πa,pop = π1,pop.RRa.
Table 4 shows prevalence odds ratios for the different
settings FP, STD clinics, and general population
settings (pop), relative to the General Practice (GP)
setting, from the same study: these are used to
inform setting-speciﬁc relative risks (RRs). The inter-
pretation of odds ratios as relative risks is an approxi-
mation that is justiﬁed by the rarity of the disease
[17]. Other prevalence data have been collected sub-
sequently [18, 19], but have not been incorporated
due to doubts about the national representativeness.
In order to use these data to map our estimates of
FOI to the general population we make the assump-
tion that the between-setting and between age-group
relative risks in the prevalence data directly inform
the hazard ratios (γa and ρs) in the incidence model
described above. For a ﬁxed duration, prevalence
ratios must be equal to incidence rate ratios, so the
assumption is that ratios of incidence are equivalent
to ratios of FOI, and of infection. We consider this
assumption further in Appendix 2.
A ﬁrst estimate of CT incidence in England (method A)
We use the odds ratio between the general popula-
tion setting and the GP setting, which informs the par-
ameter ρpop to map the FOI in the GP setting
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to provide an estimate of the FOI in women in the
general population λ˜FOIa,pop:
λ˜FOIa,pop = ρpopλ˜FOIa,GP (4)
Estimates of FOI are of interest in themselves.
However, we can easily calculate the annual popu-
lation incidence rate λ˜INC1a,pop (years
−1) for age groups
16–17, 18–20, and 21–24 years as a function of FOI
(years−1) and duration using equation (5):
λ˜INC1a,pop =
λ˜FOIa,pop
1− λ˜FOIa,popΔ
. (5)
A second estimate of CT incidence in England
(method B)
A second estimate of the annual population incidence
(years−1) can be obtained using data on duration
and data on prevalence using the relationship:
incidence=prevalence/duration, so that:
λ˜INC2a,pop =
πa,pop
Δ
, (6)
Where duration is estimated as previously described
and prevalence πa,pop is informed directly by the
data in Table 1 so λ˜INC2a,pop is estimated for the groups
18–19, 20–24, 25–29, and 30–44 years.
Full synthesis model
We can combine both of the above analyses in a single
joint synthesis using the relationship:
πa,pop = λ˜INCa,pop.Δ, (7)
where λ˜INCa,pop is informed as described in method A,
and the parameters πa,pop and Δ are informed as
described in method B. This is shown in the DAG
in Figure 1. This single joint analysis provides esti-
mates of population incidence for age groups 16–17,
18–20, 21–24, 25–29, and 30–44 years. The only age
groups for which incidence is estimated in both
methods A and B are 18–20, and 21–24 years.
However, estimates for the other age groups are also
expected to change. The full synthesis model provides
estimates for all parameters based on the entire data
ensemble. So, for example, when our knowledge of
the regression parameters described in method A are
updated by the data described in method B, estimates
of the annual population incidence rate in 16- to
17-year-olds may change.
Note that the DAG in Figure 1 also describes
methods A and B above. We remove the constraint
that prevalence = incidence × duration shown on the
DAG under the heavy black bar replacing it with
equation (6) above, and place uninformative priors
on πa,pop. This single unconstrained model then pro-
duces estimates from both methods A and B in
parallel.
Statistical estimation and model critique
The full speciﬁcation of the model is set out in
Appendix 1. Estimation was pereformed using a
Bayesian approach, where the posterior distribution
was sampled through MCMC implemented in the
WinBUGS package version 1.4.3 [10]. The Bayesian
approach was taken because of its ﬂexibility in pooling
information on complex functions of parameters: we
would expect similar results from a frequentist ap-
proach. MCMC estimation is performed by drawing
thousands of samples from the joint posterior distri-
bution. The ﬁrst 50000 iterations were discarded: this
was the ‘burn-in’ period to ensure that the distributions
had converged to the posterior. The Brooks–Gelman–
Rubin statistic [20] demonstrated convergence of
all parameters to their posterior distribution after
at most 25000 samples. The results reported below
are summary means and credible intervals of the
marginal distributions from this joint posterior based
on 200000 samples from each of two chains.
To assess goodness of ﬁt, we used the posterior
mean residual deviance, which should approximate
to the number of data points under the assumption
that the model is true [21, 22]. We compared the good-
ness of ﬁt of the combined synthesis model and the
model with separate incidence estimates: this provides
a direct assessment of the statistical assumptions.
A graphical comparison of the separate incidence
estimates is also presented. We assessed the validity
of some more speciﬁc statistical assumptions in
Appendix 2. Unless otherwise stated vague priors
are employed throughout, so that results are domi-
nated by the data. The WinBUGS code is available
along with the datasets as Supplementary online
material. It has been annotated to help readers to
understand the model.
RESULTS
Table 5 shows the posterior estimates of the annual
population incidence from method A (column 2),
method B (column 3), and the full synthesis model
(column 4). Estimates from method A are available
for the 16–17, 18–19, and 20–24 years age groups,
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method B provides estimates for the 18–19, 20–24, 25–
29, and 30–44 years age groups, and estimates for all
age groups are available from the full synthesis model.
Estimates from the full synthesis model are around a
factor of 1·5 lower than those obtained from method
A, but only marginally higher than those obtained
from method B. This is because the uncertainty in
the incidence information from the LaMontagne
data is much greater than in the combined duration
and prevalence information. This effect is shown
graphically in Figure 2, which compares the estimates
of incidence in the 18–19 and 20–24 years age groups,
and also shows the combined estimate incorporating
all data sources. Results from the full synthesis
model for all ﬁve age groups are also given in
Figure 3.
Table 5. PopulationChlamydia trachomatis incidence rate (years−1) in women by age estimated using each method
Parameter
Method A (adjusted
incidence data)
Method B (prevalence
and duration data)
Full synthesis model
(all data)
λ˜INC16--17,pop, popn incidence, 16–17 yr 0·122 (0·057–0·235) n.a. 0·082 (0·047–0·134)
λ˜INC18--19,pop, popn incidence, 18–19 yr 0·070 (0·036–0·126) 0·046 (0·028–0·072) 0·048 (0·032–0·068)
λ˜INC20--24,pop, popn incidence, 20–24 yr 0·060 (0·032–0·106) 0·031 (0·019–0·048) 0·039 (0·027–0·054)
λ˜INC25--29,pop, popn incidence, 25–29 yr n.a. 0·015 (0·009–0·023) 0·015 (0·0087–0·024)
λ˜INC30--44,pop, popn incidence, 30–44 yr n.a. 0·0078 (0·0045–0·013) 0·0080 (0·0045–0·013)
n.a., Not available.
Results given are mean (95% credible interval).
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Fig. 2. Marginal posterior distributions of incidence parameters, comparing results based on the information in incidence
study (LaMontagne), with results based on information in prevalence and duration studies (alone), and with results based
on pooling all sources of information (a) age group 18–19 years, (b) age group 18–20 years.
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Table 6 shows the estimates of the basic parameters
in the model estimated when the constraint that
prevalence = incidence × duration is excluded (col-
umn 2) and included (column 3) in the model, rep-
resenting respectively, methods A and B being
performed simultaneously in parallel, and the full
synthesis model. It shows that for most parameters:
duration, proportion symptomatic, re-infection:
infection rate ratios, age- and setting-speciﬁc risk
ratios, and prevalence parameters, the synthesis
has not contributed much additional information
over and above the ‘direct’ data already available.
However, the general population-to-GP relative risk
is lowered by a factor of about 1·35 compared to
method A and the 95% credible intervals are about
half the width.
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Fig. 3. Posterior distribution of incidence, by age range, based on all available information.
Table 6. Parameter estimates obtained from the separate models ﬁtted using methods A and B in parallel (column 2),
and from the full synthesis model (column 3)
Parameter
Separate models Full synthesis model
Mean (95% CrI) Mean (95% CrI)
CT duration and clearance rate
λA, clearance rate, asymptomatic 0·74 (0·62–0·90) 0·77 (0·64–0·95)
Δ, mean duration (years) 1·07 (0·86–1·29) 1·03 (0·82–1·25)
φ, proportion symptomatic 0·23 (0·16–0·31) 0·23 (0·16–0·32)
CT incidence: regression parameters
ηGP, re-infection:infection ratio, GP 7·31 (4·07–11·9) 7·08 (3·97–11·6)
ηFP, re-infection:infection ratio, FP 3·52 (2·09–5·52) 3·66 (2·16–5·77)
ηSTD, re-infection:infection ratio, STD 2·01 (1·17–3·17) 2·08 (1·21–3·28)
ρFP, hazard ratio, GP (reference group) 1 1
ρpop, hazard ratio, general population 0·62 (0·37–0·96) 0·46 (0·33–0·63)
ρFP, hazard ratio, FP 1·28 (1·02–1·59) 1·30 (1·03–1·61)
ρSTD, hazard ratio, STD 2·38 (1·78–3·11) 2·45 (1·83–3·20)
CT prevalence,%
π16–17,pop, general population, 16–17 yr n.a. 8·38 (4·94–13·5)
π18–19,pop, general population, 18–19 yr 4·91 (3·13–7·28) 4·85 (3·47–6·59)
π20–24,pop, general population, 20–24 yr 3·27 (2·10–4·83) 3·96 (2·89–5·30)
π25–29,pop, general population, 25–29 yr 1·54 (0·95–2·35) 1·54 (0·95–2·37)
π30–44,pop, general population, 30–44 yr 0·82 (0·50–1·28) 0·83 (0·50–1·29)
CrI, Credible interval; CT, Chlamydia trachomatis; n.a., not available; GP, general practitioner; FP, family planning; STD,
sexually transmitted disease.
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Our separate models of incidence in women aged
16–24 years included nine parameters and had a
residual deviance of 18·4 for a dataset with 21 data
points (Tables 2 and 3) representing a good ﬁt
(Table 7). When these data are combined with the
prevalence information, residual deviance increases
only marginally (19·5), indicating a lack of conﬂict
between the different sources of information on inci-
dence. Prevalence and duration data also ﬁtted
equally well. Results (not shown) with a wider uni-
form prior distribution on the duration of sympto-
matic infection, 3–12 weeks rather than 4–8 weeks,
were almost identical (<1% multiplicative change).
We therefore recommend using results from the full
synthesis model that uses all of the data, giving an esti-
mated incidence rate in females aged 16–24 years,
the population targeted by the National Chlamydia
Screening Programme, of 0·05 per year (95% CrI
0·035–0·071), and in females aged 16–44 years 0·021
per year (95% CrI 0·015–0·028).
DISCUSSION
While CT prevalence in the general UK population has
been studied [6], incidence estimates have only beenpro-
duced in clinic patients [5]. We used data on ratios
between clinic settings and the general population in
prevalence to ‘recalibrate’ the incidence data to a
lower value appropriate to a general population setting.
Wewere able to show that three independent and separ-
ate sets of data on prevalence, incidence and duration
were all consistent with each other, under a model
which captured the logical relationships between these
parameters. The possibility of clearance of infection
and re-infection during the follow-up period was also
taken into account: the effect of this is to raise incidence
estimates above the levels that are directly observed.
The estimate based on the recalibrated incidence study
was found to be compatible with an estimate based
on combining prevalence and duration information.
A certain degree of simpliﬁcation is involved. The
incidence data was collected in 2003–2004, 2–3 years
later than the NATSAL study [23], which contributes
all the general population prevalence information to
the estimates in the Adams study [6], and in a period
before intensive screening was taking place. We have
assumed that incidence is unlikely to have changed
greatly between these dates, and that our estimates
are therefore relevant to the years 2001–2005.
The application of Bayesian evidence synthesis
methods to CT epidemiology can shed light on the
value of different study designs and the relationships
between them. In addition, the ability to conﬁrm, for
example, that setting- and age-speciﬁc risk ratios in
an incidence study are compatible with odds ratios in
prevalence studies, makes it a valuable approach to epi-
demiology. However, as with any evidence synthesis
method, conclusions are limited by the quality of the
original data and the assumptions made in interpreting
them. The CT prevalence information in NATSAL
was based on self-testing in a structured population
sample and is vulnerable to response biases, although
these have been extensively analysed elsewhere [24].
The incidence data were collected in two English
areas, which were metropolitan and urban. The extent
to which these data can be assumed to be nationally
representative is not known. Finally, the estimates of
duration of asymptomatic CT duration, 1·36 (95%
CrI 1·11–1·62) years, were based on an earlier synthesis
of studies with different designs [11]. The estimate
assumes a constant clearance rate, and the model did
not allow for re-infection. However, a model including
fast and slow clearers provided no improvement in
residual deviance, and the bias introduced by not
accounting for CT re-infection in duration studies is
far lower than the bias introduced by not accounting
for clearance in studies of incidence. These ﬁndings
are supported by a recent analysis by Althaus et al.
[25] who ﬁtted a reversible model to data extracted
using the Kaplan–Meier curve from the Molano et al.
Table 7. Model ﬁt statistics for each dataset from the separate models ﬁtted using methods A and B in parallel and
the full synthesis model
Source
Number of
data points
Number of parameters Mean residual deviance
Separate models Full model Separate models Full model
Incidence 21 9 9 18·4 19·5
Prevalence 4 4 2 4·0 4·1
Duration 2 2 2 2·0 2·2
Total 27 15 13 24·3 25·7
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study [15]. They showed that a single rate model pro-
vided a good ﬁt and found that allowing for
re-infection had almost no impact on estimates of
duration. A further key assumption in [11] was that
clinic-based studies on asymptomatic women could
effectively be interpreted as studies of incident in-
fection, while studies of population screening were
picking up prevalent infection. The authors cited
several external evidence sources supporting this
assumption.
Additional validation of our estimates and of our
overall approach is available by multiplying our esti-
mated incidence rate by the number of women aged
16–24 years in England based on population census
projections for 2002 [26]. This predicts a total of
137100 (95% credible interval 95520–192500) infec-
tions. This can be compared to the 31510 and
34660 women aged 16–24 years who were treated
for CT in STD clinics in 2002 and 2003 respectively
[1]. The ratios of numbers treated to predicted total
infections in women aged 16–24 are 24% (95% CrI
16–33) for 2002 and 26% (95% CrI 18–36) for 2003.
This accords closely with the proportion of infections
in which symptoms develop estimated from the model,
and the Geisler et al. [16] ﬁndings. Therefore, had we
partitioned women as treated or untreated when esti-
mating the mean duration as is often done in dynamic
models and used recursive equations to estimate the
proportion treated from routine data, we would have
obtained almost identical results.
Although estimates of CT incidence and prevalence
in England may be of limited interest elsewhere, the
study does have wider implications. First, the fact
that incidence, prevalence and duration evidence is
internally consistent provides a degree of independent
validation of our estimates of all three parameters.
Second, it indicates that estimates of CT prevalence
or incidence in other countries can each be generated
from the other, using our estimates of duration.
Alternatively, where information is available on both
incidence and prevalence, a similar exercise could be
carried out to provide a further validation of our
results and the models on which they are based.
The study raises the question: what is the best way to
obtain accurate population-based estimates of CT inci-
dence? Further direct studyof infection and re-infection
rates in opportunistically recruited women appears
to be worthwhile. However, as well as taking account
of clearance and re-infection during follow-up, it
will probably always be necessary to ‘recalibrate’
setting-speciﬁc estimates to the general population.
Studies of either prevalence or incidence based on struc-
tured general population surveys are, therefore,
essential.
Our analysis of incidence, prevalence and duration
has relied on an essentially static epidemiological
model. The alternative would be to assess the consist-
ency of a somewhat wider evidence base within a
dynamic modelling context. For example, a dynamic
model could be estimated from the same sources of
data (incidence, prevalence, duration of symptomatic
and asymptomatic infection, proportion sympto-
matic), but also incorporating information on contact
rates and transmission rates per contact. Dynamic
modelling is not normally conceived as a synthesis
exercise: more often, incidence is seen as an ‘output’
of a dynamic model. However, the feasibility of an
evidence synthesis and consistency checking approach
to dynamic models has already been established [27].
This kind of approach would lead to a further
extension to incorporate information on incidence,
prevalence and duration of CT incidence in men.
APPENDIX 1. STATISTICAL METHODS
The schematic inﬂuence diagram (Fig. 1) sets out all
the relationships between model parameters and
data in mathematical terms. Basic parameter nodes
are shown as shaded ellipses and functional parameter
nodes as clear ellipses. Two of the basic parameters
are given informative prior distributions shown in
shaded rectangles with arrows pointing from the rec-
tangle and to the parameter. The remaining ‘basic’
parameters are given vague prior distributions which
are not shown on the ﬁgure. The ‘functional’, par-
ameters are deﬁned in terms of basic parameters, and
the deﬁnitions are shown in equations. Data which
are entered as a likelihood are shown in clear rectangles,
with arrows pointing from the parameter to the data.
A full list of basic and functional parameters along
with brief descriptions is provided in Table A1.
Most of the functional relationships have been
spelled out in the methods section as equations
(1)–(7), or in the DAG. Some expressions require
further explanation.
The expression:
κ(t) = 1− λ
C + λ.e−(λ+λC).t
λ+ λC , (8)
relates the proportion of infected individuals κ(t), who
were initially uninfected, observed after time t, to an
incidence rate λ and a clearance rate λC . This can
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be derived from Kolmogorov’s forward equations
[28, 29]. In Figure 1, the more complex relationship
represents a weighted average of two clearance
rates: one being in symptomatic and the other in
asymptomatic women. The proportion of infections
that develop symptoms is the weight, and the clear-
ance rates in each group are the reciprocals of the
mean duration of symptomatic and asymptomatic
infections.
Strictly speaking, Figure 1 sets out the relationships
as they would be if the incidence and prevalence data
were available on the exact same age groups. As the
age groupings in the studies were slightly different,
we used census information on the English female
population sizes from 2002 for each year of ages
16–44 years to reweight the parameters. Readers can
see what was done from the WinBUGS code provided
as Supplementary material, which is annotated to
make all these adjustments clear.
Prior distributions
Vague normal priors were placed on the log incidence
rate in the LaMontagne study in age group 1 and GP
setting: ln(λ1,GP,1)∼N(0,1002), and also on the rate
ratios ρs for setting s relative to the GP setting, and
γa for age group a relative to the 16–17 years age
group, and for the ratios ηs in re-infection rate to
infection rate in setting s: ρa, γs, ηs∼N(0,1002).
Priors for the duration of infection and pro-
portion symptomatic were as follows: proportion
symptomatic φ∼beta (1,1);ΔA∼n (0,1002),ΔS∼uniform
(0·0767–0·1533), i.e. uniform between 4 and 8 weeks.
Information on the proportion of patients at recruit-
ment in the GP setting, pa,GP in the LaMontagne
study who were in the re-infection group reweighted
to account for disproportionate inclusion into the
study of initially CT positive women were introduced
via informative beta priors, derived from table 1 in
LaMontagne et al. [5]. For example, in women
aged 16–19 years who were tested at GP clinics,
663+137=800 were CT negative, and 45+48 were
CT positive. So the correct weights for the infection
and re-infection groups are 800/893, and 93/893,
respectively. We repeated the same calculation for
women aged 20–24 years, and we assume the weights
are constant within these two age groups. Although
testing and treatment every 6 months interferes with
the natural history, CT-positive women are sub-
sequently placed in the re-infection group so this
does not bias the results.
Information on two parameters, ΔS and the propor-
tion of women subject to the re-infections rate, pa,GP,
was introduced via informative priors rather than
through the data likelihood. This prevents these ‘data’
from contributing directly to the global goodness-
of-ﬁt assessment. The decision to treat these inputs
differently was because the source of evidence on the
ﬁrst was expert clinical knowledge quite unrelated to
the other sources of data in the synthesis, while the
second was local to the LaMontagne study. We were
therefore interested less in the ‘goodness of ﬁt’ of this
information, and more in the goodness of ﬁt of the
other data, conditional on the priors we assigned to
these parameters. In addition, we applied the ‘cut func-
tion’ to both these parameters, a facility within the
WinBUGS programming language that prevents infor-
mation from the rest of the evidence network from
‘updating’ priors [10] so in these cases the posterior
for the parameter is the same as the informative prior.
Data likelihoods
The age-speciﬁc prevalence data Da,pop in Table 3
was given a normal likelihood on the logit scale:
logit(Da,pop)∼N(πa,pop,Va,pop), with the variance cal-
culated from the 95% CIs. The setting-speciﬁc odds
ratios (ORs) in Table 4 were handled in the same
way: logit(ORs)∼N(γs,,Vs). The data on duration of
asymptomatic infection (Table 1) was entered as a
normal likelihood: DurA∼N(ΔA,VA).
The numbers infected in Table 3 (r) are considered
as having a binomial likelihood, with parameters κa,s,i,
and denominators also shown in the table so that ra,s,i
∼B (κa,s,i (0·5),n a,s,i). The number of symptomatic
infections (r=26), reported by Geisler et al. [19] is
binomially distributed with parameter φ and denomi-
nator 115.
The WinBUGS code, available as Supplementary
material, consists of the priors and likelihoods as
described above, and the functional relationships
described exactly as in Figure 1 and in the text.
APPENDIX 2: ASSESSMENT OF
STATISTICAL MODELLING
ASSUMPTIONS
Regression analysis of the LaMontagne data
We ﬁt the following nine regression models to the 18
data points from LaMontagne shown in Table 2:
Model 1:
log(λa,s,i)=α+γa+ρs+ηi+γρas+γηai+ρηsi+γρηasi,
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Table A1. Master list of parameters
Basic parameters Priors Interpretation
Incidence
λ1,1,1 Log-normal CT infection rate in women aged 16–17 years in the GP setting
γa Log-normal Hazard ratio across age groups
ρs Log-normal Hazard ratio across settings
ηs Log-normal Setting speciﬁc re-infection to infection hazard ratios
pa,s Beta Baseline prevalence of LaMontagne sampling frame
Duration
ΔS Normal Mean duration of symptomatic CT infection
ΔA Uniform Mean duration of asymptomatic CT infection
ϕ Binomial Proportion of CT episodes in which symptoms will develop
Prevalence
πa,pop* πa,pop=π1,pop.γa Population prevalence of CT by age group
Functional
parameters Function Interpretation
Incidence
λa,s,l γaρsλ111 Infection rate for women in age group a and setting s
λa,s,2 ηsλa,s,1 Re-infection rate for women in age group a and setting s
λ˜FOIa,GP (1−pa,s).λa,s,1+pa,s.λa,s,2 Force of infection for women in age group a in the GP setting
λ˜FOIa,pop ρpopλ˜
FO
a,GP Force of infection for women in age group a in the general population
λ˜INC1a,pop
λFOIa,pop
1−λFOIa,popΔ
Incidence rate of CT for women in age group a in the general population estimated using method A
λ˜INC2a,pop πa,pop/Δ Incidence rate of CT for women in age group a in the general population estimated using method B
κ (t)a,s,i See Figure 1 Proportion of CT-negative women in age group a, setting s, and re-infection status i, expected to be CT positive after
6 months
Duration
Δ ΔSφ+ΔA(1 – φ) Mean duration of CT infection
λA
C 1/ΔA Mean clearance rate of asymptomatic CT infections
λS
C 1/ΔS Mean clearance rate of symptomatic CT infections
Prevalence
πa,pop* λ˜INCa,pop.Δ Population prevalence of CT by age group
CT, Chlamydia trachomatis.
* Prevalence is a basic parameter in method B but a functional parameter in the full synthesis model.
Incidence
of
C
hlam
ydia
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573
Model 2: log(λa,s,i)=α+γa+ρs+ηi+γρas+γηai+ρηsi,
Model 3: log(λa,s,i)=α+γa+ρs+ηi+γηai+ρηsi,
Model 4: log(λa,s,i)=α+γa+ρs+ηi+γρas+ρηsi,
Model 5: log(λa,s,i)=α+γa+ρs+ηi+γρas+γηai,
Model 6: log(λa,s,i)=α+γa+ρs+ηi+γρas,
Model 7: log(λa,s,i)=α+γa+ρs+ηi+γηai,
Model 8: log(λa,s,i)=α+γa+ρs+ηi+ρηsi,
Model 9: log(λa,s,i)=α+γa+ρs+ηi,
where: γ1, ρ1, η1, γρa1, γρ1s, γηa1,γη1i, ρηs1, ρη1i, γρηas1,
γρηa1i, γρη1si=0; γρas represents an interaction between
age and setting, γηai between age and re-infection, ρηsi
between setting and re-infection, and γρηasi is a three-
way interaction between age, setting, and re-infection.
The estimates of λa,s,i along with estimates of
duration feed into equation (8) to estimate κ (t)a,s,i:
the parameter in the likelihood function for the
LaMontagne data. Model ﬁt statistics together with
the nominal numbers of parameters for each model
are shown in Table A2. Results are based on two
chains run for 40000 samples after a 10000 burn-in.
The results show that model 8, which includes only
the main effects and an interaction between setting
and infection/re-infection status has the lowest
Deviance Information Criterion (DIC). The DIC is
a commonly used statistical measure of model ﬁt
which penalizes more complex models [22]. A plot
of the deviance residuals for model 8 showed no pro-
blems (not shown). Model 8 is identical to the one
described in the main text although it has been
re-parameterized slightly to simplify the notation.
It is only marginally better than a model that also
includes an interaction between age and setting
(model 4), or a model that assumes no interactions
(model 9).
Assumed relationship between setting-speciﬁc odds
ratios from Adams and hazard ratios in the model
for the LaMontagne data
We assume that the between-setting odds ratios are
equivalent to between-setting relative risks due to
the rare disease assumption and that these inform
the between-setting hazard ratios in LaMontagne.
This is not strictly correct as they should inform the
between-setting incidence ratios.
We assess the sensitivity of the results to this
assumption. Table A3 shows the between-setting
infection (INF) ratios (column 1), FOI ratios
(column 2), and incidence (INC) ratios (column 3),
estimated from the LaMontagne data alone. The
corresponding results from Adams (introduced in
table 4) are repeated in column 4. The INF ratios
from LaMontagne are almost identical to the odds
ratios from Adams. However, this is not a reason to
conclude that our model is better than the ‘correct’
model where they inform INC ratios. There is some
discrepancy between the INF ratios compared to the
INC or FOI ratios. The FOI and INC ratios are
almost identical.
Because of the lack of data for the general
population in LaMontagne it is incredibly difﬁcult
to correctly parameterize the model so that the
ORs inform the INC ratios. It is however possible,
although considerably more mathematically compli-
cated than the model described in this paper, to apply
the odds ratios to FOI ratios. We performed this
Table A2. Model ﬁt statistics for each of the regression
models ﬁtted to the LaMontagne data from Table 2
Model
Residual
deviance
Nominal number
of parameters DIC pD
1 18·6 18 103·2 17·9
2 15·8 14 96·2 13·2
3 19·0 10 95·8 10·1
4 14·5 12 93·1 11·9
5 22·6 12 101·1 11·9
6 21·1 10 97·7 10·0
7 24·1 8 98·9 8·0
8 17·3 8 91·9 8·0
9 22·3 6 95·0 6·0
DIC, Deviance Information Criterion; pD, effective number
of parameters [22].
Table A3. Between-setting ratios of infection (INF) rates, force of infection (FOI) rates, and incidence (INC) rates
estimated for the LaMontagne [5] data alone, along with odds ratios reported in Adams [6]
Ratio
LaMontagne LaMontagne LaMontagne Adams odds ratios
(repeated from table 4)INF ratios FOI ratios INC ratios
FP to GP 1·27 (0·59–2·48) 1·10 (0·65–1·74) 1·11 (0·61–1·88) 1·27 (1·00–1·62)
STD to GP 2·31 (1·11–4·45) 1·60 (0·95–2·53) 1·74 (0·94–2·97) 2·39 (0·72–3·33)
FP, Family planning; GP, general practitioner; STD, sexually transmitted disease clinic.
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analysis for the full synthesis model and found that
incidence changed by less than a multiplicative factor
of 5% in all age groups (mean <3%). From this, and
the fact that the INC and FOI ratios agree so closely,
we conclude that there is only very negligible bias
from not parameterizing the model so that odds ratios
inform INC ratios.
SUPPLEMENTARY MATERIAL
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